Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 16 points (0.1%) at 16,738 as of Wednesday, June 4, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,399 issues advancing vs. 1,611 declining with 145 unchanged. The Health Services industry currently is unchanged today versus the S&P 500, which is up 0.1%. A company within the industry that fell today was Boston Scientific ( BSX), up 0.5%. Top gainers within the industry include Omnicare ( OCR), up 3.2%, Smith & Nephew ( SNN), up 2.7%, Express Scripts ( ESRX), up 1.3%, Quest Diagnostics ( DGX), up 1.2% and Grifols ( GRFS), up 1.1%. TheStreet would like to highlight 3 stocks pushing the industry lower today: 3. Cyberonics ( CYBX) is one of the companies pushing the Health Services industry lower today. As of noon trading, Cyberonics is down $3.27 (-5.5%) to $56.41 on heavy volume. Thus far, 571,410 shares of Cyberonics exchanged hands as compared to its average daily volume of 208,600 shares. The stock has ranged in price between $55.27-$60.45 after having opened the day at $58.53 as compared to the previous trading day's close of $59.68. Cyberonics, Inc., together with its subsidiaries, engages in the design, development, marketing, and sale of implantable medical devices to hospitals and ambulatory surgery centers. Cyberonics has a market cap of $1.6 billion and is part of the health care sector. Shares are down 8.8% year-to-date as of the close of trading on Tuesday. Currently there are 7 analysts that rate Cyberonics a buy, no analysts rate it a sell, and none rate it a hold. TheStreet Ratings rates Cyberonics as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, growth in earnings per share, increase in net income and solid stock price performance. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Cyberonics Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.